SI9520044B - Inhibitorji Xa faktorja - Google Patents

Inhibitorji Xa faktorja Download PDF

Info

Publication number
SI9520044B
SI9520044B SI9520044A SI9520044A SI9520044B SI 9520044 B SI9520044 B SI 9520044B SI 9520044 A SI9520044 A SI 9520044A SI 9520044 A SI9520044 A SI 9520044A SI 9520044 B SI9520044 B SI 9520044B
Authority
SI
Slovenia
Prior art keywords
chg
arg
paph
leu
pro
Prior art date
Application number
SI9520044A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9520044A (en
Inventor
Fahad Al-Obeidi
Michal Lebd
A. James Ostrem
Pavel Safar
Alena Stierandova
Peter Strop
Armin Wasler
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of SI9520044A publication Critical patent/SI9520044A/sl
Publication of SI9520044B publication Critical patent/SI9520044B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SI9520044A 1994-04-26 1995-04-25 Inhibitorji Xa faktorja SI9520044B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23305494A 1994-04-26 1994-04-26
PCT/US1995/005268 WO1995029189A1 (en) 1994-04-26 1995-04-25 FACTOR Xa INHIBITORS

Publications (2)

Publication Number Publication Date
SI9520044A SI9520044A (en) 1997-10-31
SI9520044B true SI9520044B (sl) 2004-08-31

Family

ID=22875692

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9520044A SI9520044B (sl) 1994-04-26 1995-04-25 Inhibitorji Xa faktorja

Country Status (27)

Country Link
EP (2) EP0758341B1 (cs)
JP (1) JP3655632B2 (cs)
KR (1) KR100380124B1 (cs)
CN (1) CN1181091C (cs)
AT (1) ATE262536T1 (cs)
AU (1) AU707653B2 (cs)
CA (1) CA2186497C (cs)
CZ (1) CZ296439B6 (cs)
DE (1) DE69532754T2 (cs)
DK (1) DK0758341T3 (cs)
EE (1) EE03973B1 (cs)
ES (1) ES2214500T3 (cs)
FI (1) FI120494B (cs)
HU (1) HUT76346A (cs)
IL (1) IL113505A (cs)
LT (1) LT4218B (cs)
LV (1) LV11740B (cs)
NO (1) NO318759B1 (cs)
NZ (1) NZ284977A (cs)
PL (1) PL188132B1 (cs)
PT (1) PT758341E (cs)
RU (1) RU2152954C1 (cs)
SI (1) SI9520044B (cs)
SK (1) SK286094B6 (cs)
TW (1) TW409129B (cs)
WO (1) WO1995029189A1 (cs)
ZA (1) ZA953361B (cs)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0873356A1 (de) * 1995-02-17 1998-10-28 Basf Aktiengesellschaft Neue dipeptidische amidine als thrombin-inhibitoren
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
EP0868526B1 (en) * 1995-12-20 2002-08-14 Aventis Pharmaceuticals Inc. PROCESS FOR PREPARING N-ACETYL(L)-4-CYANOPHENYLALANINE Ac-(L)-Phe(4-CN)-OH AND N-ACETYL-(L)-p-AMIDINOPHENYLALANINE-CYCLOHEXYLGLYCINE-BETA-(3-N-METHYLPYRIDINIUM)-ALANINE Ac-(L)-pAph-Chg-PalMe(3)-NH2
US5766932A (en) * 1995-12-20 1998-06-16 Hoechst Marion Roussel, Inc. Process for preparing N-acetyl(L)-4-cyanophenylalanine from a mixture of the corresponding D,L ethyl esters using subtilisin
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
EP0977773A1 (en) 1997-04-14 2000-02-09 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
JP2001523226A (ja) 1997-04-14 2001-11-20 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
AU741099B2 (en) * 1997-04-14 2001-11-22 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
GB9727123D0 (en) * 1997-12-22 1998-02-25 Int Centre Genetic Eng & Bio Synthesis of diamines
EP1042287B1 (en) 1997-12-24 2005-04-20 Aventis Pharma Deutschland GmbH Indole derivatives as inhibitors of factor xa
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1016663A1 (en) * 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
EP1022268A1 (en) * 1999-01-02 2000-07-26 Aventis Pharma Deutschland GmbH Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
IL144096A0 (en) 1999-01-02 2002-05-23 Aventis Pharma Gmbh Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
WO2000040548A1 (en) * 1999-01-02 2000-07-13 Aventis Pharma Deutschland Gmbh Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
JP5088598B2 (ja) * 1999-12-14 2012-12-05 昭和電工株式会社 シアノベンジルアミン類の塩の製造方法
CN1172905C (zh) 1999-12-14 2004-10-27 昭和电工株式会社 生产氰基苄胺盐的方法
HUP0301986A2 (hu) 2000-01-28 2003-09-29 Aventis Pharma Deutschland Gmbh. Eljárás acetil-amidinofenilalanil-ciklohexilglicil-piridinioalanin-amidok elżállítására, valamint kiindulási anyagok és köztitermékek
EP1127884A1 (en) * 2000-02-26 2001-08-29 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them
DE10029015A1 (de) 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa
NZ526269A (en) 2000-12-06 2004-11-26 Aventis Pharma Gmbh Guanidine and amidine derivatives as factor Xa inhibitors having antithrombotic effect
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
EP1485345B1 (de) 2002-03-11 2008-06-25 Curacyte AG Hemmstoffe der urokinase, ihre herstellung und verwendung
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
WO2006047415A2 (en) 2004-10-26 2006-05-04 Janssen Pharmaceutica, N.V. Factor xa compounds
EP1724269A1 (en) 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors
DE102005044319A1 (de) 2005-09-16 2007-03-22 Curacyte Chemistry Gmbh 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
EP1918718A1 (de) * 2006-10-31 2008-05-07 Roche Diagnostics GmbH Verfahren und Vorrichtungen zur elektrochemischen Bestimmung von Faktor Xa-Inhibitoren in Blutproben
US20080254036A1 (en) 2007-04-13 2008-10-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
DE102023133734A1 (de) 2023-12-01 2025-06-05 Technische Universität Darmstadt, Körperschaft des öffentlichen Rechts Schnelle Bestimmung von Analytgehalten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275153A (en) * 1978-08-03 1981-06-23 American Hospital Supply Corporation Analytical fluorogenic substrates for proteolytic enzymes
CA1161431A (en) * 1979-05-11 1984-01-31 Lars G. Svendsen Tripeptide derivatives
US4469679A (en) * 1983-02-16 1984-09-04 Smithkline Beckman Corporation Octapeptide vasopressin antagonists
HU191961B (en) * 1984-08-02 1987-04-28 Richter Gedeon Vegyeszet Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
HU206372B (en) * 1990-09-03 1992-10-28 Richter Gedeon Vegyeszet Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same
DE69321344D1 (de) * 1992-02-14 1998-11-05 Corvas Int Inc Inhibitoren der thrombose

Also Published As

Publication number Publication date
CN1147261A (zh) 1997-04-09
CA2186497C (en) 2008-06-17
NZ284977A (en) 1998-09-24
SI9520044A (en) 1997-10-31
FI964317A0 (fi) 1996-10-25
EP1384725A3 (en) 2007-02-21
AU2368395A (en) 1995-11-16
WO1995029189A1 (en) 1995-11-02
HU9602954D0 (en) 1996-12-30
PL188132B1 (pl) 2004-12-31
DK0758341T3 (da) 2004-06-28
CZ314096A3 (en) 1997-05-14
JP3655632B2 (ja) 2005-06-02
ZA953361B (en) 1996-01-12
NO318759B1 (no) 2005-05-02
EE9600146A (et) 1997-04-15
ES2214500T3 (es) 2004-09-16
EE03973B1 (et) 2003-02-17
EP0758341A1 (en) 1997-02-19
FI120494B (fi) 2009-11-13
LT96151A (en) 1997-05-26
JPH10503477A (ja) 1998-03-31
CZ296439B6 (cs) 2006-03-15
ATE262536T1 (de) 2004-04-15
PT758341E (pt) 2004-08-31
SK286094B6 (sk) 2008-03-05
CN1181091C (zh) 2004-12-22
NO964553D0 (no) 1996-10-25
FI964317A7 (fi) 1996-10-25
DE69532754T2 (de) 2005-03-10
HUT76346A (en) 1997-08-28
EP1384725A2 (en) 2004-01-28
SK136696A3 (en) 1997-05-07
LV11740A (lv) 1997-04-20
KR100380124B1 (ko) 2003-08-02
AU707653B2 (en) 1999-07-15
RU2152954C1 (ru) 2000-07-20
NO964553L (no) 1996-12-27
TW409129B (en) 2000-10-21
DE69532754D1 (de) 2004-04-29
IL113505A0 (en) 1995-07-31
LT4218B (en) 1997-09-25
PL317067A1 (en) 1997-03-03
EP0758341B1 (en) 2004-03-24
LV11740B (en) 1997-12-20
CA2186497A1 (en) 1995-11-02
IL113505A (en) 1999-12-31

Similar Documents

Publication Publication Date Title
SI9520044B (sl) Inhibitorji Xa faktorja
Hannas et al. The role of matrix metalloproteinases in the oral environment
CA2712512C (en) Use of serine protease inhibitors in the treatment of skin diseases
ES2567706T3 (es) Tetrapéptidos protectores para cuidado cutáneo
de Bentzmann et al. Pseudomonas aeruginosa virulence factors delay airway epithelial wound repair by altering the actin cytoskeleton and inducing overactivation of epithelial matrix metalloproteinase–2
UA89684C2 (ru) Двухслойная фармацевтическая дозированная форма с модифицированным высвобождением нимесулида
McCarthy et al. Reconstitution of autophagy ameliorates vascular function and arterial stiffening in spontaneously hypertensive rats
Manfro et al. Effect of different concentrations of chlorhexidine on bond strength of primary dentin
US20220370360A1 (en) Compositions for treating viral infections and methods for same
CN104398390B (zh) 牙本质底涂‑冲洗底涂剂及其方法
Lungarella et al. Pulmonary vascular injury in pancreatitis: evidence for a major role played by pancreatic elastase
CN104159599B (zh) 双功能肽
Bakowska et al. Collagenase and gelatinase activities in bronchoalveolar lavage fluids during bleomycin‐induced lung injury
Stefanovič et al. Cell surface aminopeptidase A and N activities in human glomerular epithelial cells
EP1257582B1 (en) Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
JPS61263927A (ja) 修飾ヒルデイン類、その製法およびこれを有効成分として含む薬用製剤
JP3573803B2 (ja) 皮膚外用剤
Gacko et al. Activities of proteases in parietal thrombus of aortic aneurysm
Ingerman-Wojenski et al. Model system to study interaction of platelets with damaged arterial wall: II. Inhibition of smooth muscle cell proliferation by dipyridamole and AH-P719
AU2003294360B2 (en) Method to increase fibronectin
Frankel et al. Induction of unilateral pulmonary fibrosis in the rat by cadmium chloride
Zhou et al. Study on related indexes of the coagulation and fibrinolytic system after renal ischemia reperfusion injury in Wistar rats
TW199863B (cs)
de Wet et al. Metabolic functions of the lung
WO2019131406A1 (ja) トロンビンの抑制作用を指標とした皮膚状態改善剤のスクリーニング方法、及びトロンビン作用阻害剤を含む皮膚状態改善剤

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20111128